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Background: Melanoma and squamous cell carcinoma of the skin are characterized
by an altered glucose metabolism, but little is known about metabolic changes in
precancerous skin lesions such as actinic keratosis (AK). Here, we studied the central
carbon metabolism and immune cell infiltrate of actinic keratosis lesions before, under,
and 4 weeks after treatment with topical diclofenac (Solaraze®).
Methods: This study was designed as a prospective, randomized, controlled,
monocentric investigation (ClinicalTrials.gov Identifier: NCT01935531). Myeloid and T
cell infiltration was analyzed in skin biopsies from 28 patients by immunohistochemistry.
Furthermore, immune cell activation was determined via quantitative real-time PCR
(IFN-γ , IL-10, CSF1, TGF-β, IL-6). Glucose, amino acid and Krebs’ cycle metabolism
was studied by mass spectrometry prior, during and after treatment with topical
diclofenac. Biopsies from sun-exposed, untreated, healthy skin served as controls.
Results: Increased lactate and decreased glucose levels suggested accelerated
glycolysis in pre-treatment AK. Further, levels of Krebs’ cycle intermediates other than
citrate and amino acids were elevated. Analysis of the immune infiltrate revealed less
epidermal CD1a+ cells but increased frequencies of dermal CD8+ T cells in AK.
Treatment with diclofenac reduced lactate and amino acid levels in AK, especially in
responding lesions, and induced an infiltration of dermal CD8+ T cells accompanied
by high IFN-γ mRNA expression, suggesting improved T cell function.
Discussion: Our study clearly demonstrated that not only cancers but also
pre-malignant skin lesions, like AK, exhibit profound changes in metabolism, correlating
with an altered immune infiltrate. Diclofenac normalizes metabolism, immune cell
infiltration and function in AK lesions, suggesting a novel mechanism of action.
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INTRODUCTION
Actinic keratosis (AK) is a skin lesion characterized by disordered
keratinocyte proliferation due to excessive ultraviolet (UV)
exposure. It is regarded as an in situ squamous cell carcinoma
as it can progress to invasive squamous cell carcinoma (1).
Prevalence of AK is high, especially in older individuals.
Epidemiologic studies in Germany demonstrated a prevalence of
11.5 % among 60–70-year old patients (2). In the Netherlands,
the prevalence is even higher with 49.0 and 28.1% of men
and women with a mean age of 72 years suffering from one
or more AK lesions (3). A similar high prevalence of AK is
found in Australia, where 52% of men older than 70 years are
affected (3, 4).
Topical diclofenac is a standard treatment modality for AK.
However, the mechanism of action is not fully understood
yet (5, 6). Inhibition of cyclooxygenase (COX-1/-2) and
induction of apoptosis are discussed as possible underlying
mechanisms (7–11).
We demonstrated inhibitory effects of diclofenac on
tumor cell proliferation that were not related to COX
inhibition (12). Diclofenac inhibited the oncogene MYC
and significantly decreased glucose transporter-1 (GLUT-1),
lactate dehydrogenase A (LDHA), and monocarboxylate
transporter-1 (MCT-1) gene expression in line with a decrease
in lactate secretion and glucose uptake. Of importance, in
a murine glioma model, diclofenac treatment diminished
intratumoral lactate levels, delayed glioma growth and
rescued IL-12 production of tumor-infiltrating dendritic
cells (DCs) (13).
Increased glycolysis under normoxia, known as the “Warburg
effect” (14), enables tumor cells to synthesize building blocks
such as non-essential amino acids and nucleotides for protein
and nucleic acid biosynthesis. Moreover, this phenotype induces
a highly immunosuppressive metabolic milieu with low glucose
and high lactate levels (15). Several studies demonstrated
strong effects of lactic acid on immune cell populations in
vitro and in vivo (16). In vitro, administration of lactic
acid inhibited proliferation and activation of human cytotoxic
CD8T cells, while LDHA-mediated production of lactate in
tumor cells constrained IFN-γ production in tumor-infiltrating
T cells, resulting in a loss of immune surveillance in a
mouse melanoma model (17, 18). Furthermore, activation and
antigen expression of human dendritic cells was suppressed
by lactic acid in vitro (19). Accordingly, high intratumoral
concentrations of lactate correlate with decreased patient
survival in cancers such as head-and-neck cancers and
melanoma (18, 20).
This shift to glucose metabolism results in diminished
citrate synthesis and, thus, availability of acetyl-CoA, which in
turn contributes to cancer aggressiveness via changes in the
acetylation state of proteins (21). Likewise, changes in cancer
amino acidmetabolism can affect tumor infiltrating immune cells
(15, 16). However, no data are currently available on glucose and
amino acid metabolism in AK.
In this study, we examined the metabolism and the immune
infiltrate of AK in response to topical diclofenac treatment.
MATERIALS AND METHODS
Study Design
This study was designed as a prospective, randomized, controlled,
monocentric investigation, with patients acting as their own
control. The study was approved by the Institutional Review
Board and the Ethics Committee of the University of Regensburg
as well as by the German Federal Institute for Drugs
and Medical Devices. Written informed consent had been
obtained from each patient before enrolment. The number
of patients required for this trial had been calculated during
a prestudy statistical consultation (F. Zeman, M. Koller,
University Hospital Regensburg). The trial was registered prior
to the start of the study at clinicaltrials.gov (ClinicalTrials.gov
Identifier: NCT01935531).
Inclusion and Exclusion Criteria
The main inclusion criteria were oral and written informed
patient consent; Caucasian male or female patients aged ≥18
years; a negative pregnancy test in women of childbearing
age; clinical diagnosis of AK and a minimum of 3 AK
lesions (Table 1).
The main exclusion criteria were concomitant UV
phototherapy, pregnancy or lactation, women of child-bearing
age, who did not use highly efficient contraceptive methods,
skin diseases that may interfere with the response evaluation
of the study treatment, Fitzpatrick skin type IV-VI, any topical
AK treatment of the dorsal hands during the 4 weeks preceding
study treatment, topical or systemic treatment with retinoids,
systemic treatment with cytostatic drugs during the 3 months
preceding study therapy, any known intolerance to diclofenac
or to any other ingredient of Solaraze
R©
3% gel (Almirall
Hermal GmbH, Reinbek, Germany), systemic treatment with
diclofenac, conditions that may interfere with a patient’s
ability to understand the study and give written informed
consent, simultaneous participation in another clinical study or
participation in another clinical study in the 30 days directly
preceding inclusion, and suspected lack of compliance.
Study Treatment
At visit 1, three AKs were randomly determined and documented
as target lesions. If there were only 3 available AKs, all lesions
were numbered consecutively (1–3). If more than 3 AKs were
available, preferably similar AKs were chosen as target lesions
and additional AKs were also documented and generally called
study lesions. The first target lesion was biopsied (4–5mm
punch) prior to treatment at visit 1 after local anesthesia with
Mepivacain (Mecain R© 1%, Actavis, Munich, Germany). Another
skin biopsy (target lesion number 2) was biopsied at the end
of the 12-week treatment period. Target lesion number 3 was
biopsied 4 weeks after cessation of treatment (Table 1). A control
biopsy in sun damaged, untreated, healthy skin (e.g., capillitium,
arms, legs) was additionally obtained in 10 suited patients upon
patient’s informed consent at visits 1 and 3. Biopsied tissues
were immediately wraped in aluminum foil, snap-frozen in
liquid nitrogen and stored at −80◦C. This procedure did not
exceed 1 min.
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TABLE 1 | Flow diagram of the study.
Three percent diclofenac in 2.5% hyaluronic acid gel
(Solaraze R© 3% gel) was applied 1 cm beyond the single AK
twice daily on the study lesions. The localization and the size
of the AK study lesions were documented in a chart in the
CRF. Photographs from the treatment area were taken. Study
participants were advised to avoid direct sun exposure in the
treatment area.
Clinical Evaluation
At visits 2 and 3, treatment efficacy was evaluated. Complete
clearance was documented if a lesion was no longer visible
and also imperceptible to the touch. Partial remission was
documented if a lesion was clinically improved compared to
photographs taken before treatment start. No remission was
documented in case of not improved lesions. In case of small
lesions that had been largely removed by the biopsy, no
evaluation of treatment efficacy was possible.
Histological and Immuno-Histochemical
Analysis
The sections were stained following standard protocols for
hematoxylin-eosin (HE) and evaluated by a dermatopathologist.
AKs were graded as follows: In grade AK I atypical keratinocytes
were restricted to the lower third of the epidermis. In grade AK
II, atypical keratinocytes extended to the lower two-thirds of the
epidermis. In grade AK III, full thickness atypia of the epidermis
was found (22).
For immuno-histochemical staining with CD1a, CD4, CD8,
CD68, and GLUT-1 paraffin-embedded skin samples were
stained and evaluated by a blinded laboratory technician as
described previously (23). The following antibodies were used:
rabbit anti-humanmonoclonal anti-CD1a (clone EP3622), rabbit
anti-human monoclonal anti-CD4 (clone SP35), mouse anti-
human CD8 (clone C8/144B), rabbit anti-human monoclonal
CD68 (clone SP251) and rabbit anti-humanmonoclonal GLUT-1
(clone SP168). All antibodies were purchased at Biozol, Eching,
Germany. The selected pixels of the evaluated images were
expressed as the percentage of the total area.
Quantitative Real-Time PCR (qRT-PCR)
Snap-frozen biopsies were homogenized using TissueLyser and
QIAshredder columns (Qiagen, Hilden, Germany). Subsequent
isolation of total cellular RNA was performed using the
RNeasy Mini Kit (Qiagen). RNA quantification and control
of integrity was measured on RNA Nano LabChips using the
2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA,
USA). Complementary DNA was synthesized with a M-MLV
Reverse Transcriptase kit (Promega, Madison, WI, USA) and
was amplified by qPCR with the QuantiFast SYBR Green PCR
Kit (Qiagen) using the Mastercyler Ep Realplex (Eppendorf,
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Hamburg, Germany). The following primers were used for
human: GLUT-1, 5′-AACTCTTCAGCCAGGGTCCAC-3′ and
5′-CACAGTGAAGATGATGAAGACGTAGGG-3′; LDHA,
5′-GGTTGGTGCTGTTGGCATGG-3’ and 5′-TGCCCCAGC
CGTGATAATGA-3′; LDHB, 5′-GATGGTGGTTGAAAGTGCC
TATGAAGTC−3′ and 5′-AGCCACACTTAATCCAATAGC
CCA-3′; CSF1, 5′-CGAGCAGGAGTATCACCGAGGA-3′ and
5′-ATGTAATTTGGCACGAGGTCTCCATCTG-3′; COX1,
5′-CTACGAGCAGTTCTTGTTCAACACC-3′ and 5′-ATGACA
TCCACAGCCACATGCAG-3′; COX2, 5′-CCAGAGCAGGCA
GATGAAATACCAG-3′ and 5′-TCGATGTCACCATAGAGT
GCTTCC-3′; TGFβ , 5′-CAGCAACAATTCCTGGCGATA-3′
and 5′-ATTTCCCCTCCACGGCTCAA-3′; IL10, 5′-GCAACC
TGCCTAACATGCTTCGAG-3′ and 5′-CTGGGTCTTGGT
TCTCAGCTTGGG-3′; IL6, 5′-TGCTTCCAATCTGGATTC
AATGAGG-3′ and 5′-GCTCTGGCTTGTTCCTCACTACTC-3′
and IFNγ , 5′-CTAATTATTCGGTAACTGACTTGA-3′ and
5′-ACAGTTCAGCCATCACTTGGA-3′. PCR results were
normalized to the control gene 18S, 5′-ACCGATTGGATGGTT
TAGTGAG-3′ and 5′-CCTACGGAAACCTTGTTACGAC-3′.
Determination of Metabolites
Tissue specimens were weighted and homogenized in 600 µL
of aqueous methanol (80:20, v/v) three times at 6,500 rpm for
30 s each with a 30-s pause in-between using the Precellys tissue
homogenizer and Precellys vials filled with 1.4-mm ceramic
beads (CK14 Soft Tissue Homogenizing Kit, Bertin Instruments,
Montigny-le-Bretonneux, France). During homogenization, 40
µL of an internal standard mix containing stable isotope labeled
analogs of the analytes were added. Subsequently, samples were
centrifuged at 9560×g for 5min at 4◦C and the supernatant
was transferred to a 1.5-mL glass vial. The pellet was washed
twice with 200 µL of 80% methanol, centrifuged at 13800 ×
g for the last wash, and all supernatants were combined. The
combined extracts were then evaporated to complete dryness
and reconstituted in 100 µL of water containing 0.1% formic
acid. The extracts were centrifuged to obtain a clear sample
and a 50-µL aliquot was taken for subsequent analysis of
tryptophan metabolites and amino acids. The remaining extract
was evaporated to complete dryness for GC-MS analysis of
glucose, organic acids, and diclofenac.
Tryptophan metabolites were measured in the extracts
by liquid chromatography-tandem mass spectrometry (HPLC-
MS/MS) as previously described (24). Amino acids were analyzed
by HPLC-MS/MS after derivatization with propyl chloroformate
using a 10-µL sample aliquot as described previously (25).
Analysis of glucose, diclofenac, glycolysis and TCA cycle
intermediates was performed by GC-MS. The dried sample
residue was subjected to methoximation and silylation and
subsequent GC-MS analysis using the derivatization protocol
and instrumental setup previously described (26). An injection
volume of 1 µL and splitless injection was employed. Starting
at 50◦C, the GC oven temperature was ramped first at 5◦C/min
to 120◦C and, then, at 8◦C/min to 300◦C, where it was held for
5min. Quantification was performed using a calibration curves
for each analyte with the corresponding stable isotope labeled
analog serving as internal standard.
Statistical Analysis
Statistics were performed using the GraphPad 7 software.
Significances were determined by Mann-Whitney and Kruskal-
Wallis test.
RESULTS
Increased Metabolic Activity in Actinic
Keratosis Lesions
A total of 28 patients with a mean age of 72.9 ± 8.4 years
and histologically confirmed AK were included in the study.
Thirteen patients (46.4%) were diagnosed with grade I AK, while
fourteen (50%) and one patient (3.6%) had grade II and III
AK, respectively.
Gene expression of glucose transporter-1 (GLUT-1)
was significantly enhanced in AK lesions compared to
normal, sun-exposed skin controls (Figure 1A). Protein
expression in epidermis was also tentatively increased
(Figures 1B,C), but did not reach a statistically significant
level (p= 0.1352). No significant differences in gene expression
were detected for lactate dehydrogenase A (LDHA) and
LDHB; likewise, the ratio between LDHA and LDHB was
not altered (Figure 1A, Supplemental Figure 1A). As
diclofenac blocks cyclooxygenase (COX) activity and COX-
1 and−2 are overexpressed in many tumor entities (27),
we also analyzed the expression of COX-1 and−2 in AK
biopsies. Neither COX-1 nor COX-2 mRNA expression was
altered in AK (Figure 1A), but the ratio between COX-
1 and COX-2 was significantly decreased in AK lesions
suggesting a predominance of the “tumor-specific” COX-2 in AK
(Supplemental Figure 1B).
Although GLUT-1 protein was not upregulated, significantly
decreased glucose levels and a 2-fold increase in lactate
levels were detected in pre-malignant AK lesions (Figure 1D),
consistent with accelerated glycolytic activity. Interestingly, TCA
metabolites were dysregulated in AK. The tissue concentrations
of citrate were significantly reduced in AK lesions compared to
controls, while those of fumarate and malate were significantly
increased (Figure 1E).
We also determined amino acid levels, as tryptophan,
arginine or glutamine metabolism can undergo profound
changes in tumors (16). Levels of both kynurenine and
tryptophan were increased in AK, and so was the kynurenine-
to-tryptophan ratio (Figure 1F, Supplemental Figure 1C),
which indicates increased indoleamine 2,3-dioxygenase
(IDO) activity. Additionally, AK exhibited higher
concentrations of almost all amino acids with the
exception of ornithine and methionine (Figure 1G,
Supplemental Figure 1D).
In summary, AK lesions showed the characteristic metabolic
signs of tissues sustaining increased proliferation, namely
increased glycolysis and uptake of amino acids. The increased
levels of fumarate and malate in the presence of decreased levels
of citrate suggest anaplerosis to sustain amino acid biosynthesis
and redox homeostasis.
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FIGURE 1 | Increased lactate and amino acid levels in actinic keratosis lesions. (A) qRT-PCR analysis of GLUT-1, LDHA, LDHB, COX1, and COX2 gene expression in
actinic keratosis lesions (AK) and control biopsies (co) of sun-exposed, untreated, healthy skin in 28 patients. (B) Representative staining of GLUT-1 in actinic keratosis
lesion and control biopsy. (C) Immunohistochemical staining of GLUT-1 in epidermis, dermis and skin appendages in actinic keratosis lesions and control biopsies.
The selected pixels of the evaluated images were expressed as the percentage of the total area. (D–G) Determination of intratumor metabolite levels by mass
spectrometry. The dark line indicates the median. *p < 0.05, **p < 0.01, ***p < 0.001 (Mann-Whitney test). Ala, alanine; Gln, glutamine; Asn, asparagine; Orn,
ornithine; Gly, glycine; Arg, arginine.
Reprogramming of AK Metabolism After
Treatment With Diclofenac
AK lesions were treated for 3 months with topical diclofenac
(Solaraze R©) and then observed for another 4 weeks to
record response to treatment. They were devided based
on the response to diclofenac treatment to responders
(normal skin 4 weeks after treatment) and non-responders
(persistent AK 4 weeks after treatment). In both groups
similar diclofenac levels could be detected in AK biopsies
(data not shown).
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FIGURE 2 | Metabolic response to diclofenac in AK lesions. (A–H) Temporal changes in intratumor metabolite levels of (A) glucose, (B) lactate, (C) tryptophan, (D)
glutamine, (E) alanine, (F) phenylalanine, (G) fumarate, and (H) citrate, in actinic keratosis lesions and control skin biopsies. Left graphs show all patients pre, on
(diclo), and post treatment with diclofenac. Right graphs show non-responders (NR, n = 8) and responders (R, n = 12) to diclofenac on (diclo) and post treatment
compared to controls (co). The dark lines indicate the median. *p < 0.05, **p < 0.01 (Kruskal-Wallis test).
Treatment of AK lesions with diclofenac for 12 weeks did
not affect glucose tissue levels (Figure 2A). There was a slight,
but insignificant increase in glucose tissue levels 4 weeks after
cessation of treatment. There were also no significant differences
in glucose tissue levels between responders and non-responders.
While overall levels of lactate in AK lesions did not change
under treatment with diclofenac compared to levels before
initiation of treatment, there was a drop 4 weeks after completion
of treatment (Figure 2B). However, subgroup analysis showed,
that responders had already experienced a strong reduction of
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TABLE 2 | Decreased glucose, amino acid, and TCA metabolites in AK lesions responding to diclofenac.
Differences between levels of metabolic pathways between pre [pre (AK)], on (Diclo) and post treatment with diclofenac in all patients or, separately, in non-responders and responders
to solaraze®. Data are medians of metabolite concentrations in pmol/mg tissue. Red color represents high concentrations, green color represents low concentrations of metabolites.
lactate levels 12 weeks into the treatment with diclofenac. After
treatment, also non-responders reached lactate levels comparable
to the control indicating a delayed response (Figure 2B).
Tryptophan levels were not significantly decreased during
and after treatment with diclofenac and reached control
levels in responding lesions while non-responding lesions
exhibited still elevated levels after treatment (Figure 2C). The
kynurenine-to-tryptophan ratio reached control levels in both
non-responders and responders (Supplemental Figure 1E).
Accordingly, glutamine, alanine and phenylalanine levels
and all other analyzed amino acids were decreased in
responding lesions only and reached normal skin levels
(Figures 2D–F, Table 2). No changes were observed in the
glutamine/glutamate ratio (Supplemental Figure 1F). Notably,
no significant changes in levels of Krebs’ cycle intermediates
fumarate, malate and succinate could be observed during
and after treatment with diclofenac (Figure 2G, Table 2).
Interestingly, citrate levels remained low in AK lesions
compared to controls both during and 4 weeks after cessation
treatment (Figure 2H).
In summary, these data suggest that diclofenac treatment
impacts at least in part the metabolic state of AK lesions.
Decrement of Epidermal Langerhans Cells
in Actinic Keratosis Lesions
We examined whether the immune cell composition in AK is
altered as compared to control biopsies. To this end, markers
defining typical immune cell subsets in skin such as Langerhans
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cells (LC, CD1a), macrophages (CD68), and T cells (CD4, CD8)
were stained immunohistochemically. While less CD1a+ LCs
were detected in the epidermis and skin appendages of patients
with AK, no differences were found in the dermis (Figures 3A,E).
CD68+macrophages were located in epidermis, dermis and skin
appendages and a higher frequency of macrophages could be
detected in the dermis of AK (Figures 3B,E).
LCs play a key role as immune sentinels at the skin barrier
surface as they act as antigen-presenting cells and regulate
differentiation and effector functions of T cells. Therefore, we
next examined skin infiltrating T cells. CD4+ T cells were
more prominent than CD8+ T cells in all dermal layers.
No difference in CD4+ T cell infiltration between epidermis,
dermis, skin appendages and neither between control biopsy
and AK was observed (Figure 3C). Interestingly, CD8+ T
cells infiltrated into the dermis of AK, whereas only a few
CD8+ T cells were present in healthy skin (Figures 3D,E).
Beside surface markers, immune cells can be characterized by
functional parameters such as cytokine expression. To further
describe the immune infiltrate of AK, we analyzed cytokines
that are secreted by T cells and/or myeloid cells and are
involved in the regulation of inflammation. The expression of
colony stimulating factor 1 (CSF1), transforming growth factor
β (TGF-β) as well as interleukin-10 (IL-10), and -6 (IL-6) was
not changed in AK (Figure 3F) in comparison to healthy skin
but interferon-γ (IFN-γ )the most prominent anti-tumoral T
cell (and NK cell) cytokine (28), was significantly elevated in
AK (Figure 3F).
Diclofenac Counteracts Immune Cell
Alterations in AK Lesions
Our previous studies revealed that diclofenac has a strong impact
on metabolism and immune cell infiltration in tumors (13).
Therefore, we examined whether diclofenac also influenced the
immune cell composition in AK lesions. As already shown in
Figure 3A, CD1a expressing LCs were markedly reduced in
precancerous AK lesions compared to healthy, sun-exposed,
untreated skin. Application of diclofenac increased the number
of epidermal CD1a+ cells in responders by trend (Figure 4A,
Supplemental Figure 2) and elevated dermal infiltrating CD1a+
cells (Figure 4B, Supplemental Figure 2).
Of interest, the number of CD8+ T cells in the epidermis as
well as in the dermis increased in responders during treatment
indicating that diclofenac promoted CD8+ T cell infiltration in
these skin layers (Figures 4C,D, Supplemental Figure 2). In the
dermis, also an infiltration of CD8+ T cells in non-responding
lesions could be observed (Figure 4D, Supplemental Figure 2).
In contrast to CD8+ T cells, we did not detect differences
in the frequency of CD4+ T cells, neither in the epidermis
nor in the dermis of patients with AK before, during and after
the treatment (data not shown). The level of dermal CD68+
macrophages decreased after diclofenac treatment (Figures 4E,F,
Supplemental Figure 2).
Next, we examined local cytokine and growth factor levels
during and after treatment with diclofenac. Interestingly, IFN-
γ mRNA expression was significantly elevated during treatment
with diclofenac in responders (Figure 4G), which correlated with
higher CD8+ T cell infiltration (Figures 4C,D). Additionally,
IL-10 mRNA expression levels were increased in AK lesions
indicating the presence of an anti-inflammatory reaction
(Figure 4H). Expression of IL-6 was enhanced by trend in
non-responding lesions during treatment with diclofenac, while
expression levels of CSF1 was not altered (data not shown).
TGF-β levels were reduced in all biopsies after treatment with
diclofenac but no differences between responding and non-
responding lesions could be detected (data not shown).
Therefore, treatment with diclofenac led to a strong
infiltration of dermal CD8+ T cells along with an increase in type
II IFN and IL-10 expression.
DISCUSSION
Diclofenac, a nonsteroidal anti-inflammatory drug (NSAID),
is used for the field treatment of AK lesions. However,
its mode of action is not fully understood. Inhibition of
cyclooxygenase (COX-1/-2) and, consequently, angiogenesis and
cellular proliferation is a proposed mechanism of action (7, 8).
Also, COX-independent mechanisms, such as the induction of
apoptosis by NSAIDs, are discussed (9–11). Interestingly, COX-
2 inhibition is discussed to elicit anti-proliferative response in
human cancer cell lines via induction of endoplasmatic reticulum
stress (29). So far, no clinical data exist on the impact of diclofenac
treatment on glucose and amino acid metabolism.
Accelerated glucose metabolism is a well-known feature of
melanomas as the BRAF oncogene causes the upregulation of
genes involved in glycolysis (30). Increased GLUT-1 expression
could also be detected in BRAF wild-type skin lesions, such as
squamous cell carcinomas (SCC) and AK (31) indicating that
increased glucose metabolism contributes to tumor development
of cutaneous neoplasia. Analyses of AK biopsies revealed high
levels of lactate accompanied by increased GLUT-1 mRNA
expression and decreased glucose levels. While diclofenac did not
influence glucose levels in either responding or non-responding
AK, the lactate concentration was significantly reduced in
AK lesions after treatment. This is in line with our previous
findings showing that diclofenac inhibits lactate secretion in
glioma and leukemia cell lines (12, 13, 32). Of importance,
responding lesions exhibited reduced lactate levels already during
therapy, whereas non-responding lesions exhibited decreased
lactate levels after therapy. In these patients, an elongation of
the therapy with diclofenac might further reduce lactate levels
in these highly metabolic AK. In line, Ulrich et al. and Nelson
et al. reported a better response to diclofenac therapy after longer
treatment (11, 33).
High intratumoral lactate concentrations correlate with
decreased patient survival in head-and-neck tumors and
melanoma patients (18, 20) and limit T cell function.
Additionally, accelerated glucose metabolism can lead to
glucose deprivation resulting in diminished T cell effector
functions (34, 35). Based on the profound metabolic changes
in AK lesions, we analyzed immune cell infiltration during
treatment and observed a strong infiltration of epidermal
and dermal CD8+ T cells in responding AK, accompanied
with strong mRNA expression of IFN-γ. In contrast, another
publication showed an NSAID mediated inhibition of IFN-γ
secretion in NK cells and γδ-T cells (36). Cytotoxic CD8+ T
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FIGURE 3 | Actinic keratosis induces changes in the skin immune infiltrate. (A–D) Immunohistochemical staining of (A) CD1a, (B) CD68, (C) CD4, and (D) CD8 in
epidermis, dermis and skin appendages in actinic keratosis lesions (AK) and control biopsies (co) of sun-exposed, untreated, healthy skin in 28 patients. The selected
pixels of the evaluated images were expressed as the percentage of the total area. (E) Representative stainings of CD1a (upper images), CD8 (middle images), and
CD68 (lower images) in actinic keratosis lesions and control biopsies. (F) qRT-PCR analysis of CSF1, TGF-β, IFN-γ , IL-6, and IL-10 gene expression in actinic
keratosis lesions and control skin biopsies. The dark lines indicate the median. *p < 0.05, **p < 0.01, ***p < 0.001 (Mann-Whitney test).
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FIGURE 4 | Diclofenac induced an increased immune response. (A–E) Immunohistochemical staining of (A,B) CD1a, (C,D) CD8, and (E,F) CD68 in epidermis and
dermis in actinic keratosis lesions (AK) and control skin biopsies (co). The selected pixels of the evaluated images were expressed as the percentage of the total area.
(G,H) qRT-PCR analysis of (G) IFN-γ and (H) IL-10 gene expression in actinic keratosis lesions and control skin biopsies. Left graphs show all patients pre, on (diclo)
and post treatment with diclofenac. Right graphs show non-responders (NR, n = 8) and responders (R, n = 12) to diclofenac on (diclo) and post treatment compared
to controls (co). The dark lines indicate the median. *p < 0.05, **p < 0.01, ***p < 0.001 (Kruskal-Wallis test).
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cells play a pivotal role in the elimination of virus-infected and
malignant cells (37, 38) and for most cancers, an infiltration
with cytotoxic T cells is associated with a good prognosis (28).
In our previous work, we clearly demonstrated in a murine B16
melanoma model, that inhibition of lactate production by LDHA
downregulation improves immunosurveillance and restrains
tumor in an IFN-γ dependent manner (18). Strong infiltration
with CD8+ T cells was also described after topical treatment
with ingenol mebutate, a standard drug for AK (39, 40), but in
this study the number of CD4+ T cells and myeloid cells was
also increased, suggesting an unspecific inflammatory reaction.
IL-10 was also enhanced in AK lesions during treatment
with diclofenac. The principal function of IL-10 is the limitation
of inflammatory responses, but it is also able to regulate
the growth and differentiation of several cell types, namely
immune cells, endothelial cells as well as keratinocytes (41). We
hypothesize, that IL-10 is produced by infiltrating macrophages
or immunosuppressive T cell populations and represents a
possible mechanism to suppress the immune response in AK.
We detected significantly less CD1a expressing Langerhans
cells (LC) in the epidermis of AK. After the treatment with
diclofenac, responders show by trend a normal skin infiltrate with
higher numbers of LCs. Interestingly, in a murine glioma model,
diclofenac also resulted in higher frequencies of intra-tumoral
CD11c+CD86+ DCs (13). Of importance, these DCs were also
more activated and produced higher amounts of IL-12 which in
turn could lead to the activation of T cells. This phenomenon
might have occurred in our study and could explain the increased
CD8+ T cell associated immune response.
Shevchuk et al. found decreased epidermal CD1a+ and
CD207+ LCs in SCC and decreased numbers of CD207+ LCs
in precancerous AK lesions (42). In contrast, a recent study
described higher numbers of LCs in AK. This discrepancy might
be due to the fact that (39) we used healthy sun-exposed skin
as control whereas Emmert and co-workers selected non-sun-
exposed skin. In line with other studies, our data show a clear
dermal infiltration of CD68+ macrophages as well as CD8+ T
cells in AK (39, 43).
Beside alterations in glucose metabolism with decreased
glucose and increased lactate levels, we also detected higher
concentrations of several amino acids in AK compared to
untreated, sun-exposed skin. After treatment with diclofenac,
lactate and almost all amino acids reached normal skin levels in
responding biopsies. As glycolytic intermediates such as pyruvate
are used to produce amino acids, accelerated glycolysis could
partially explain increased amino acid levels in AK lesions.
Precancerous AK lesions might require accelerated glucose
and amino acid metabolism to synthesize building blocks and
gain energy to allow rapid proliferation of keratinocytes (44).
Recently, it has been discussed that targeting glutaminolysis is
a possible approach to treat SCC. As AK is a precancerous
lesion leading to SCC this approach may also be appropriate for
treatment of AK (45).
Tryptophan levels were elevated in AK lesions but the
kynurenine/tryptophan ratio reached control levels after
treatment. Tryptophan is metabolized by indoleamine
2,3-dioxygenase (IDO), which catalyzes the conversion of
tryptophan to kynurenine. IDO is expressed by different
cell types and can lead to tryptophan depletion. Disturbed
tryptophan metabolism and high expression of IDO have been
described in different tumor entities, e.g., in esophageal SCC
but also in patients with dermatitis or psoriasis (46, 47). Of
importance, Hennequart et al. could show a COX-2 driven
expression of IDO-1 in tumor cells and COX-2 inhibitors were
able to diminish IDO-1 expression (48). Thus, diclofenac is able
to affect tryptophan metabolism in AK.
In summary, we could clearly show that not only cancers
but also pre-malignant skin lesions exhibit profound changes
in metabolism, correlating with an altered immune infiltrate.
Both, metabolism and immune infiltration are influenced by
topical diclofenac treatment indicating that these alterations
contribute to the mode of action beside the well-known
inhibition of cyclooxygenase.
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